]>
IRCT2014121420086N2 IRCT 2015-01-08 Shahid sdoughi university of medical sciences Effect of cabergoline on laboratory findings and menstural irregularity in PCOS women Cabergoline in PCOS women Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinaemia 2012-06-21 anticipated 110 Complete https://irct.ir/trial/17834 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2-3 Polycystic ovary syndrom. Intervention 1: In case group metformin 1000 mg/day Cabergoline, 0.5 ml tablet one/week for 4 months was given. Intervention 2: In control group metformin 1000 mg/day and cabergoline pelacebo weekly for 4 months were given.
public Dr.Akram Jowkar
Shahid sdoughi hospital-Department of Endocrinology
Yazd Iran (Islamic Republic of) +98 35 3822 4000 akjowkar@gmail .com Shahid sdoughi university of medical sciences scientific Dr.Akram Jowkar
Shahid sdoughi hospital-Department of Endocrinology
Yazd Iran (Islamic Republic of) +98 35 3822 4000 akjowkar@gmail.com Shahid sdoughi university Iran (Islamic Republic of) 110 PCOS women with increased serum prolactin concentration [1.5 fold more than normal level (>37.5ng/ml)]; between 18-35 years old, who referred to endocrinology clinic of Khatamal Anbiaa Cilinic, Shahid Sadoughi University of Medical Sciences, were examined for other causes of increased prolactin levels such as TSH test, hypophis MRI for detection of prolactinema and other disorders or tumors that can increase prolactin, and then women who had diagnosed as PCOS according to the latest AES standards enrolled in the study. Patients who had other endocrine disorders (such as thyroid disorders), history of cardiovascular disease, history of using the increasing prolactin drugs, women who wanted to be pregnant, and who couldn’t tolerate the cabergoline were excluded from the study. 18 years 35 years Female E28.2 Polycystic ovarian syndrome Treatment - Drugs Placebo In case group metformin 1000 mg/day Cabergoline, 0.5 ml tablet one/week for 4 months was given. In control group metformin 1000 mg/day and cabergoline pelacebo weekly for 4 months were given. Menstural irregularity. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: standard questionniare. Serum testosteron. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA). Serum DHEAS. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA). Serum prolactin. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA). Weight. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: With SECA scale per kilogram. Shahid sdoughi university of medical sciences Approved 2012-06-17 Shahid Sadoughi University of Medical Sciences Shahid Sadoughi University of Medical Sciences- Bahonar sq- Yazd Yazd Iran (Islamic Republic of)